24398

    544210

    EMCURE

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    EMCURE PHARMACEUTICALS L Share Price Today

    EMCURE PHARMACEUTICALS L is currently trading at ₹1960.1, up by ₹49.19 from the previous close. The stock touched an intraday high of ₹1999.00 and a low of ₹1904.00 during the latest trading session. Over the past one year, EMCURE PHARMACEUTICALS L has delivered a return of 33.84%, while the stock has gained 4.07% in the last one month.

    EMCURE PHARMACEUTICALS L performance

    Today’s low Today’s high
    ₹ 1904.00 ₹ 1999.00
    ₹ 1960.10
    52 week low 52 week high
    ₹ 1260.00 ₹ 1999.00
    ₹ 1960.10
    Open Price ₹ 1923.80
    Prev. Close ₹ 1910.90
    Volume (Shares) 267249.00
    Total traded value ₹ 5238.34
    Upper Circuit ₹ 2101.90
    Lower Circuit ₹ 1719.90
    info

    Investment Returns

    Over 1 Month 4.07% Over 3 Months 13.73% Over 6 Months 30.54% Over 1 Year 33.84%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    EMCURE PHARMACEUTICALS L fundamentals


    • Market cap (Cr) 37,179.20
    • P/E Ratio (TTM) 49.43
    • Beta 0.54
    • Book Value / share 195.62
    • Return on equity 12.79%
    • EPS (TTM) 39.64
    • Dividend yield 0.19%
    • Net profit/quarter (Cr) 233.70
    info icon alternate text
    • Market cap (Cr) 37,098.60
    • P/E Ratio (TTM) 49.43
    • Beta 0.44
    • Book Value / share 195.62
    • Return on equity 12.79%
    • EPS (TTM) 39.64
    • Dividend yield 0.19%
    • Net profit/quarter (Cr) 233.70
    info icon alternate text

    EMCURE PHARMACEUTICALS L Financials

    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 1467.70
    Operating Expense 1195.95
    Net Profit 233.70
    Net Profit Margin (%) 15.92
    Earnings Per Share (EPS) 12.33
    EBITDA 406.18
    Effective Tax Rate (%) 23.69
    Particulars DEC 2025 (Values in Cr)
    Revenue 1418.31
    Operating Expense 1213.09
    Net Profit 258.85
    Net Profit Margin (%) 18.25
    Earnings Per Share (EPS) 13.65
    EBITDA 409.65
    Effective Tax Rate (%) 17.65
    Particulars SEP 2025 (Values in Cr)
    Revenue 1260.60
    Operating Expense 1125.46
    Net Profit 117.62
    Net Profit Margin (%) 9.33
    Earnings Per Share (EPS) 6.21
    EBITDA 247.34
    Effective Tax Rate (%) 25.50
    Particulars JUN 2025 (Values in Cr)
    Revenue 1096.57
    Operating Expense 948.93
    Net Profit 122.79
    Net Profit Margin (%) 11.19
    Earnings Per Share (EPS) 6.48
    EBITDA 246.02
    Effective Tax Rate (%) 25.88
    Particulars MAR 2025 (Values in Cr)
    Revenue 1278.19
    Operating Expense 1114.53
    Net Profit 139.56
    Net Profit Margin (%) 10.91
    Earnings Per Share (EPS) 7.37
    EBITDA 267.03
    Effective Tax Rate (%) 24.99
    Particulars MAR 2026 (Values in Cr)
    Revenue 5243.19
    Operating Expense 4483.44
    Net Profit 732.96
    Net Profit Margin (%) 13.97
    Earnings Per Share (EPS) 38.67
    EBITDA 1309.19
    Effective Tax Rate (%) 22.37
    Particulars MAR 2025 (Values in Cr)
    Revenue 4381.92
    Operating Expense 4073.02
    Net Profit 317.13
    Net Profit Margin (%) 7.23
    Earnings Per Share (EPS) 16.95
    EBITDA 765.64
    Effective Tax Rate (%) 25.85
    Particulars MAR 2024 (Values in Cr)
    Revenue 3497.66
    Operating Expense 3426.68
    Net Profit 160.83
    Net Profit Margin (%) 4.59
    Earnings Per Share (EPS) 8.89
    EBITDA 570.83
    Effective Tax Rate (%) 19.54
    Particulars MAR 2023 (Values in Cr)
    Revenue 3107.09
    Operating Expense 3013.95
    Net Profit 160.06
    Net Profit Margin (%) 5.15
    Earnings Per Share (EPS) 9.07
    EBITDA 557.69
    Effective Tax Rate (%) 24.62
    Particulars MAR 2022 (Values in Cr)
    Revenue 3387.24
    Operating Expense 2903.50
    Net Profit 446.81
    Net Profit Margin (%) 13.19
    Earnings Per Share (EPS) 24.66
    EBITDA 927.34
    Effective Tax Rate (%) 27.51
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 234.65
    ROE % 19.12
    ROCE % 20.01
    Total Debt to Total Equity 0.45
    EBITDA Margin 19.39
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 162.97
    ROE % 19.35
    ROCE % 18.23
    Total Debt to Total Equity 0.86
    EBITDA Margin 19.18
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 138.30
    ROE % 25.03
    ROCE % 20.75
    Total Debt to Total Equity 1.01
    EBITDA Margin 20.40
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 109.90
    ROE % 32.98
    ROCE % 25.00
    Total Debt to Total Equity 1.06
    EBITDA Margin 23.80
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 125.68
    ROE % 20.14
    ROCE % 21.08
    Total Debt to Total Equity 1.11
    EBITDA Margin 24.83
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 159.61
    ROE % 12.79
    ROCE % 14.36
    Total Debt to Total Equity 0.49
    EBITDA Margin 17.47
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 106.82
    ROE % 8.52
    ROCE % 10.08
    Total Debt to Total Equity 0.89
    EBITDA Margin 16.32
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 101.84
    ROE % 9.01
    ROCE % 10.69
    Total Debt to Total Equity 0.94
    EBITDA Margin 17.95
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 94.69
    ROE % 22.26
    ROCE % 20.50
    Total Debt to Total Equity 0.79
    EBITDA Margin 27.38
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 127.27
    ROE % 19.95
    ROCE % 18.88
    Total Debt to Total Equity 0.69
    EBITDA Margin 26.54
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 165.29
    Total Assets 8232.72
    Total Liabilities 8232.72
    Total Equity 4641.55
    Share Outstanding 18
    Price to Book Ratio 6.72
    Return on Assets (%) 8.27
    Return on Capital (%) 12.68
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 232.40
    Total Assets 7806.16
    Total Liabilities 7806.16
    Total Equity 3121.76
    Share Outstanding 18
    Price to Book Ratio 0.00
    Return on Assets (%) 6.38
    Return on Capital (%) 9.56
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 458.25
    Total Assets 6672.53
    Total Liabilities 6672.53
    Total Equity 2649.66
    Share Outstanding 18
    Price to Book Ratio 0.00
    Return on Assets (%) 7.97
    Return on Capital (%) 10.98
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 313.29
    Total Assets 6063.46
    Total Liabilities 6063.46
    Total Equity 2114.14
    Share Outstanding 18
    Price to Book Ratio 0.00
    Return on Assets (%) 10.92
    Return on Capital (%) 15.78
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 523.53
    Total Assets 6807.39
    Total Liabilities 6807.39
    Total Equity 2368.01
    Share Outstanding 18
    Price to Book Ratio 0.00
    Return on Assets (%) 6.14
    Return on Capital (%) 9.68
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 13.79
    Total Assets 5416.11
    Total Liabilities 5416.11
    Total Equity 3024.36
    Share Outstanding 18
    Price to Book Ratio 6.72
    Return on Assets (%) 5.85
    Return on Capital (%) 8.62
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 32.12
    Total Assets 4756.93
    Total Liabilities 4756.93
    Total Equity 1935.09
    Share Outstanding 18
    Price to Book Ratio 0.00
    Return on Assets (%) 3.38
    Return on Capital (%) 4.8
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 141.01
    Total Assets 4615.84
    Total Liabilities 4615.84
    Total Equity 1841.86
    Share Outstanding 18
    Price to Book Ratio 0.00
    Return on Assets (%) 3.46
    Return on Capital (%) 4.56
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 47.88
    Total Assets 4323.18
    Total Liabilities 4323.18
    Total Equity 1712.52
    Share Outstanding 18
    Price to Book Ratio 0.00
    Return on Assets (%) 10.33
    Return on Capital (%) 13.58
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 260.72
    Total Assets 4863.19
    Total Liabilities 4863.19
    Total Equity 2301.77
    Share Outstanding 18
    Price to Book Ratio 0.00
    Return on Assets (%) 8.64
    Return on Capital (%) 11.66
    Particulars MAR 2025 (Values in Cr)
    Net Income 971.34
    Cash from Operations 1098.56
    Cash from Investing -94.00
    Cash from Financing -813.95
    Net change in Cash -56.25
    Free Cash Flow 1320.33
    Particulars MAR 2024 (Values in Cr)
    Net Income 727.22
    Cash from Operations 1320.89
    Cash from Investing -712.51
    Cash from Financing -164.20
    Net change in Cash 220.52
    Free Cash Flow 1596.66
    Particulars MAR 2023 (Values in Cr)
    Net Income 747.21
    Cash from Operations 947.32
    Cash from Investing -467.68
    Cash from Financing -145.39
    Net change in Cash 133.77
    Free Cash Flow 1337.92
    Particulars MAR 2022 (Values in Cr)
    Net Income 972.54
    Cash from Operations 1079.38
    Cash from Investing -788.79
    Cash from Financing -151.85
    Net change in Cash -172.43
    Free Cash Flow 1482.58
    Particulars MAR 2021 (Values in Cr)
    Net Income 657.32
    Cash from Operations 904.86
    Cash from Investing -251.84
    Cash from Financing -188.90
    Net change in Cash 259.06
    Free Cash Flow 1050.53
    Particulars MAR 2025 (Values in Cr)
    Net Income 427.71
    Cash from Operations 624.39
    Cash from Investing -435.61
    Cash from Financing -49.24
    Net change in Cash 73.42
    Free Cash Flow 820.54
    Particulars MAR 2024 (Values in Cr)
    Net Income 199.91
    Cash from Operations 651.83
    Cash from Investing -171.07
    Cash from Financing -287.74
    Net change in Cash 126.14
    Free Cash Flow 901.09
    Particulars MAR 2023 (Values in Cr)
    Net Income 212.33
    Cash from Operations 589.91
    Cash from Investing -270.43
    Cash from Financing -54.51
    Net change in Cash 180.42
    Free Cash Flow 861.57
    Particulars MAR 2022 (Values in Cr)
    Net Income 616.42
    Cash from Operations 598.38
    Cash from Investing -188.99
    Cash from Financing -342.96
    Net change in Cash -309.06
    Free Cash Flow 772.45
    Particulars MAR 2021 (Values in Cr)
    Net Income 557.44
    Cash from Operations 888.54
    Cash from Investing -831.16
    Cash from Financing 30.97
    Net change in Cash -25.32
    Free Cash Flow 988.63
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 33.64 13.96 1.62 257.79 23.12 38.85
    BLISS GVS PHARMA LTD 454.10 36.50 4.03 4816.01 118.35 552.90
    CIPLA LTD. 1466.00 33.09 3.43 118430.12 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 465.55 21.78 3.36 1370.16 256.40 482.70
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 33.64 23.52 4.33 257.79 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 518.30 23.23 4.04 1498.44 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8090.05 105.72 23.17 20225.13 7630.00 9850.00
    BLISS GVS PHARMA LTD 454.10 49.09 4.16 4816.01 118.35 552.90

    EMCURE PHARMACEUTICALS L shareholding pattern

    Holding
    8.83%
    77.83%
    4.87%
    8.46%
    0.04%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    EMCURE PHARMACEUTICALS L Technicals Summary

    1960.10 2.57 redarrow
    red-green-graph indicator
    0 Bearish
    16 Bullish
    • 5 Days 1899.90
    • 26 Days 1844.80
    • 10 Days 1883.90
    • 50 Days 1796.80
    • 12 Days 1878.00
    • 100 Days 1714.50
    • 20 Days 1857.90
    • 200 Days 1606.00
    1915.30 PIVOT
    First Support 1895.60 First Resistance 1930.60 Second Support 1880.30 Second Resistance 1950.30 Third Support 1860.60 Third Resistance 1965.60
    RSI 60.63 ADX 32.69 MACD 33.21 Williams % R -23.49 Commodity Channel Index (CCI) 104.09
    Date 2026-07-30 Week 91324.00 Same Day 37860.00 Month 72221.00
    1 Year 0.55 3 Year 0.84
    Over 1 Month
    4.07% down
    Over 1 Year
    33.84% down
    Over 3 Months
    13.73% down
    Over 3 Years
    12.02% down
    Over 6 Months
    30.54% down
    Over 5 Years
    0.00% down

    EMCURE PHARMACEUTICALS L Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    14 Aug 2025 3.0 Final 14 Aug 2025 Equity shares
    Dividend date Dividend amount Dividend type Record date Instrument type
    14 Aug 2025 3.0 Final 14 Aug 2025 Equity shares

    Top Gainers

    Top Losers

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Emcure Pharmaceuticals Ltd?

    Answer Field

    Emcure Pharmaceuticals Ltd share price is for NSE ₹ 1,960.10 & for BSE ₹ 1,955.85 as on Jul 31 2026 03:30 PM.

    What is the Market Cap of Emcure Pharmaceuticals Ltd Share?

    Answer Field

    The market cap of Emcure Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 31 2026 03:30 PM.

    What is the 52 Week High and Low of Emcure Pharmaceuticals Ltd?

    Answer Field

    The 52 Week High and Low of Emcure Pharmaceuticals Ltd for NSE is ₹ 1,999.00 and ₹ 1,260.00 and for BSE is ₹ 1,999.75 and ₹ 1,260.10.

    What is 1 year return for Emcure Pharmaceuticals Ltd?

    Answer Field

    The 1 year returns on the stock has been 33.84%.

    What is the P/E Ratio of Emcure Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 31 2026 03:30 PM the price-to-earnings (PE) ratio for Emcure Pharmaceuticals Ltd share is 49.43.

    What is the PB ratio of Emcure Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 31 2026 03:30 PM, the price-to-book (PB) ratio for Emcure Pharmaceuticals Ltd share is 195.62.

    How to Buy Emcure Pharmaceuticals Ltd Share?

    Answer Field

    You can trade in Emcure Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Emcure Pharmaceuticals Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Emcure Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Emcure Pharmaceuticals Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |